Aurinia Pharmaceuticals (IKAP) AI Stock Analysis

1 Followers

Aurinia Pharmaceuticals

(Frankfurt:IKAP)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Extended U.S. ExclusivityThe Teva settlement supports continued U.S. exclusivity for voclosporin for roughly another decade, protecting Aurinia’s principal commercial franchise from this generic challenge. That legal outcome can sustain pricing power, prescription economics, and cash generation while the company develops its longer-term strategy.

Negative Factors

Single-Product ConcentrationReliance on LUPKYNIS as the primary commercial product concentrates revenue and operating performance in one therapy. Any disruption to demand, reimbursement, prescribing, adherence, or the product’s commercial position would therefore have an outsized effect on Aurinia’s growth and cash-generation outlook.

Aurinia Pharmaceuticals (IKAP) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 2.29B
Dividend Yield: ―
Average Volume (3M): 100
Price to Earnings (P/E): 7.2
Beta (1Y): 0.18
Revenue Growth: 15.36%
EPS Growth: 298.04%
Country: Germany
Employees: 128
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Aurinia Pharmaceuticals Business Overview & Revenue Model

Company Description

Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solut...

Aurinia Pharmaceuticals Earnings Call Summary

Earnings Call Date:Feb 25, 2026(Q4-2025)|% Change Since:19.52%|Next Earnings Date:Mar 03, 2027

Earnings Call SentimentPositive

The call highlights robust commercial momentum for LUPKYNIS with double-digit top-line growth, materially improved cash generation, a strong balance sheet and share repurchases. Management provided constructive 2026 guidance and disclosed promising early clinical results for aritinercept. Offsetting these positives are a significant one-time tax benefit that materially boosted reported net income, termination of a pediatric study (creating regulatory follow-up risk), emerging competition (Gazyva), limited near-term transparency on quarterly performance, and early-stage development uncertainties (ADAs). Overall, the positives—sustained product revenue growth, strong cash flow, and advancing pipeline—outweigh the headwinds, though some risks remain.

Positive Updates

Strong LUPKYNIS Commercial Growth

Net product sales of LUPKYNIS for full year 2025 were $271.3M, up 25% year-over-year from $216.2M. Management reported LUPKYNIS sales grew 25% in 2025 and expects 2026 net product sales of $305M–$315M (up 12%–16% vs. 2025).

Negative Updates

Net Income Heavily Influenced by One-Time Tax Benefit

Q4 2025 net income included an income tax benefit of $175.1M and FY2025 included $173M related to the release of a valuation allowance on deferred tax assets. Management notes this benefit primarily drove the large YoY net income and EPS improvements, indicating part of the profitability gain is non-recurring.

Company Guidance

On the call Aurinia provided 2026 guidance of total revenue of $315–$325 million (up 11%–15% vs. 2025) and net product sales of LUPKYNIS of $305–$315 million (up 12%–16% vs. 2025); that outlook is framed by FY‑2025 results of total revenue $283.1M (up 20% vs. $235.1M in 2024, or +26% excluding a $10M 2024 milestone), LUPKYNIS sales $271.3M (up 25% YoY), net income $287.2M (driven in part by a $173M income tax benefit), diluted EPS $2.07, operating cash flow $135.7M (up 206% YoY), cash and investments of $398M, and recent share repurchases of 12.2M shares for $98.2M that reduced fully diluted shares from 149.8M to 139.7M; Q4 highlights included revenue $77.1M, LUPKYNIS sales $74.2M (both +29% YoY), Q4 net income $210.8M (driven by a $175.1M tax benefit), diluted EPS $1.53, and Q4 operating cash flow $45.7M (up 52% YoY).

Aurinia Pharmaceuticals Risk Analysis

Aurinia Pharmaceuticals disclosed 33 risk factors in its most recent earnings report. Aurinia Pharmaceuticals reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

1 New Risk

1..Under Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025, we identified important factors that could affect our financial performance and could cause our actual results for future periods to differ materially from our anticipated results or other expectations, including those expressed in any forward-looking statements made in this Quarterly Report. There has been no material change in our risk factors subsequent to the filing of our prior reports referenced above. However, the risks described in our reports are not the only risks we face. Additional risks and uncertainties that we currently deem to be immaterial or not currently known to us, as well as other risks reported from time to time in our reports to the SEC, also could cause our actual results to differ materially from our anticipated results or other expectations.Q2, 2026

Aurinia Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:IKAP against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RIGL	81Outperform	$912.70M	2.90	96.49%	―	3.31%	221.64%
MLTX	52Neutral	$995.75M	-3.14	-79.95%	―	―	-37.48%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VERA	51Neutral	$2.21B	-5.46	-84.13%	―	―	-63.94%
OMER	48Neutral	$1.32B	9.52	-109.40%	―	―	―
ALMS	41Neutral	$867.72M	-1.72	-102.97%	―	-63.11%	15.36%

* Healthcare Sector Average

Performance Comparison

DE:IKAP and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:IKAP	Aurinia Pharmaceuticals	14.51	2.34	19.23%
OMER	Omeros Corporation	18.18	11.60	176.29%
RIGL	Rigel Pharmaceuticals	51.29	15.17	42.00%
MLTX	Moonlake Immunotherapeutics	11.56	1.27	12.34%
VERA	Vera Therapeutics, Inc.	31.97	6.75	26.76%
ALMS	Alumis Inc.	6.55	1.83	38.77%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Aurinia Pharmaceuticals AI Stock Analysis